As a recognized leader in conducting complex, global oncology and hematology trials, PRA has contributed expert services critical to the approval of important drugs such as Avastin®, Inlyta®, Sutent®, Nexavar®, Tarceva®, Velcade® and Mariqbo®.
Experience and Expertise
During the last five years, PRA has participated in more than 400 oncology and hematology clinical trials and consulting projects globally in every phase and virtually every indication, including supportive care. The 225+ clinical trials (Phase I-IV) across all indications involved 54,700+ patients at 8,900+ sites globally.
Key Areas of Oncology & Hematology Expertise
The following tables summarize PRA’s clinical study and consulting experience in our key oncology and hematology indications during the last five years.
Investigator Relations & Patient Access
PRA provides support for clinical trials at every level. Our network of global expertise, patient access and investigator alliances allows us to provide an accomplished service for oncology and hematology studies of all types.
PRA’s advantages include:
- Supportive care study experience.
- Global investigator network to provide access to nearly all geographical areas, including emergent markets such as Asia, Latin America and Eastern Europe for patient recruitment.
- Access to Citeline™ products (SiteTrove, TrialPredict and TrialTrove)—together with our internal investigator network—enables us to conduct accurate feasibility studies and more effectively recruit oncology/hematology patients to our studies. This approach results in faster study start-ups, thereby reducing overall development timelines for our sponsors.
